Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

December 31, 2027

Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

Verapamil

"1\. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"

DRUG

Bisoprolol

"1\. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"

DRUG

Placebo

"1\. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"

Trial Locations (4)

4000

NOT_YET_RECRUITING

Department of Cardiology, Zealand University Hospital, Roskilde

5000

RECRUITING

Department of Cardiology, Odense University Hospital, Odense

8200

RECRUITING

Department of Cardiology, Aarhus University Hospital, Aarhus N

8800

NOT_YET_RECRUITING

Department of Cardiology, Regional Hospital Viborg, Viborg

All Listed Sponsors
collaborator

Viborg Regional Hospital

OTHER

collaborator

Zealand University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

lead

Morten Steen Kvistholm Jensen

OTHER

NCT05569382 - Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter